MedTrace Logo

Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients

NCT07441733 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-11

No results posted yet for this study

Summary

This single-institution pilot study uses a pre- and post-implementation design to evaluate the implementation of ICG fluorescent imaging for sentinel lymph node biopsy (SLNB) in an Italian hospital.

Conditions

Interventions

PROCEDURE

ICG used as a tracer for sentinel lymph node

ICG used as a tracer for sentinel lymph node instead of technetium 99

PROCEDURE

technetium 99 used as a tracer for sentinel lymph node

technetium 99 used as a tracer for sentinel lymph node instead of ICG

Sponsors & Collaborators

  • Casa di Cura Dott. Pederzoli

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-07
Primary Completion
2025-03-31
Completion
2026-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441733 on ClinicalTrials.gov